Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone612-379-8854
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$642.99 million
Profitability
Miscellaneous
Employees2,000
OptionableOptionable
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Tuesday, October 30th. Shareholders of record on Friday, November 9th will be given a dividend of $0.32 per share on Friday, November 23rd. This represents a $1.28 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Thursday, November 8th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) issued its quarterly earnings results on Tuesday, October, 30th. The biotechnology company reported $0.98 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.95 by $0.03. The biotechnology company had revenue of $163 million for the quarter, compared to analysts' expectations of $162.34 million. BIO-TECHNE had a return on equity of 14.09% and a net margin of 19.19%. The company's quarterly revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.90 earnings per share. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
How can I listen to BIO-TECHNE's earnings call?
BIO-TECHNE will be holding an earnings conference call on Tuesday, February 5th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8665484713.
What price target have analysts set for TECH?
8 equities research analysts have issued 12 month price targets for BIO-TECHNE's shares. Their forecasts range from $154.00 to $230.00. On average, they anticipate BIO-TECHNE's stock price to reach $185.00 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Has BIO-TECHNE been receiving favorable news coverage?
News stories about TECH stock have trended negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIO-TECHNE earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
- Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
- Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
- Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
- Mr. Gerry Andros, VP of Sales and Marketing
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.26%), BTIM Corp. (0.29%), Summit Creek Advisors LLC (0.21%), Retirement Systems of Alabama (0.13%), Assenagon Asset Management S.A. (0.08%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which major investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including BTIM Corp., Assenagon Asset Management S.A., Riverbridge Partners LLC, CENTRAL TRUST Co, Summit Creek Advisors LLC, State of Alaska Department of Revenue, Nisa Investment Advisors LLC and Bank of Montreal Can. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth and John L Higgins. View Insider Buying and Selling for BIO-TECHNE.
Which major investors are buying BIO-TECHNE stock?
TECH stock was acquired by a variety of institutional investors in the last quarter, including Oakbrook Investments LLC, BB&T Corp, Meeder Asset Management Inc., Diversified Trust Co, Retirement Systems of Alabama and Strs Ohio. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $162.13.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $6.12 billion and generates $642.99 million in revenue each year. The biotechnology company earns $126.15 million in net income (profit) each year or $4.07 on an earnings per share basis. BIO-TECHNE employs 2,000 workers across the globe.
What is BIO-TECHNE's official website?
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
